Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI's Expert Panel

<p><strong>New Delhi:</strong> The result for Phase 3 clinical trial of Bharat Biotech&rsquo;s Covaxin vaccine is out as the Subject Expert Committee (SEC) under India's drug regulator on Tuesday gave approval to efficacy data for the Coronavirus jab.</p> <p>According to the data submitted by Bharat Biotech, Covaxin has shown the efficacy of 77.8 per cent from the trial conducted on 25,800 subjects across the country, news agency ANI quoted citing sources.</p> <p>The approval was given to country's only indigenous Covid-19 vaccine after an expert panel met earlier in the day to review Covaxin's trial data.</p> <p>As per the procedue, SEC will not send Covaxin's Phase 3 trial data to Drugs Controller General of India (DCGI) for review.</p> <p><em><strong>(This is a developing story. More details awaited.)</strong></em></p>

from covid-19 https://ift.tt/3vNwTTF